封面
市場調查報告書
商品編碼
1329135

脊柱生物製品的全球市場

Spine Biologics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年,全球脊柱生物製品市場將達到 29 億美元

在 COVID-19 後商業環境發生變化的情況下,全球脊柱生物製劑市場預計 2022 年將達到 20 億美元,2022 年至 2030 年年複合成長率為 4.3%,預計到 2030 年將達到 29 億美元本報告分析的細分市場之一——脊柱植入物,預計年複合成長率3.9%,到分析期結束時將達到 14 億美元。鑑於大流行後的持續復甦,未來八年骨移植段的成長修正為 4.9% 的年複合成長率。

美國市場預計將成長 5.544 億美元,中國年複合成長率為 6.7%

到 2022 年,美國脊柱生物製品市場預計將達到 5.544 億美元。中國作為世界第二大經濟體,預計到 2030 年市場規模將達到 5.938 億美元,2022 年至 2030 年分析期間年複合成長率為 6.7%。其他值得注意的地域市場包括日本和加拿大,預計 2022 年至 2030 年將分別成長 2.5% 和 3.5%。在歐洲,德國的年複合成長率預計約為 3.1%。

受訪企業示例

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

目錄

第1章 調查方法

第2章 執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳大利亞
  • 印度
  • 韓國
  • 亞太地區其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP14981

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Spine Biologics Market to Reach $2.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Spine Biologics estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at aCAGR of 4.3% over the period 2022-2030. Spinal Allografts, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bone Graft Substitutes segment is readjusted to a revised 4.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $554.4 Million, While China is Forecast to Grow at 6.7% CAGR

The Spine Biologics market in the U.S. is estimated at US$554.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$593.8 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Select Competitors (Total 46 Featured) -

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Spine Biologics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Spinal Allografts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cell-based Matrix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Spine Biologics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers (ASCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: China 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: France 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • INDIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: India 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: India 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • AFRICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030

IV. COMPETITION